DIAGNOSTIC_TEST
cardiac PET/MRI
Patients will undergo cardiac PET/MRI scanning at 30±5 days and at 90±5 days post-stroke.
Status
Unknown
Phase
Not applicable
Enrollment
12
Locations
1
Results
Not posted
Publications
0
Study summary
Patients with stroke have a 25x higher risk of cardiovascular complications within the first 30 days of the event compared to individuals without stroke. The mechanisms behind these complications are not well understood. Evidence suggests that inflammation plays a central role. With the present proof-of-concept prospective cohort study, the investigators aim to demonstrate that patients develop cardiac inflammation after stroke by performing positron emission tomography (PET) magnetic resonance imaging (MRI) of the heart within 15 days after stroke. As a secondary aim, the investigators will evaluate whether post-stroke cardiac inflammation persists at 3 months after stroke. The control group will be comprised of age- and sex-matched individuals without stroke.
Interventions
DIAGNOSTIC_TEST
Patients will undergo cardiac PET/MRI scanning at 30±5 days and at 90±5 days post-stroke.
DIAGNOSTIC_TEST
Measurement of a panel of 92 systemic inflammatory markers on patients' blood samples at 30±5 days and at 90±5 days post-stroke
DIAGNOSTIC_TEST
NT-proBNP is useful both in the diagnosis and prognosis of heart failure and is considered to be a gold standard biomarker in heart failure. Measurement of NT-proBNP on patients' blood samples at 30±5 days and at 90±5 days post-stroke
Timeline
First posted
Mar 30, 2023
Study start
Jul 1, 2023
Primary completion
Sep 2, 2024
Study completion
Sep 2, 2025
Results posted
Not reported
Registry updated
Mar 13, 2024
Outcomes
Cardiac Inflammation Levels at 30±5 Days Post-Stroke measured by PET/MR Scanning
Time frame · At 30 days±5 post stroke
Cardiac inflammation as measure on PET/MR scanning.
Cardiac Inflammation Levels at 90±5 Days Post-Stroke measured by PET/MR Scanning
Time frame · At 90±5 days compared to first 30 days±5 post-stroke
Cardiac inflammation as measure on PET/MR scanning.
Change in B-Type Natriuretic Peptide (NT-proBNP) and HS-TnT levels between 30±5 days and 90±5 days post-stroke.
Time frame · At 90±5 days compared to first 30±5 days post stroke
Change in levels of NT-proBNP and HS-TnT between 30±5 and 90±15 days post-stroke.
Change in systemic inflammatory markers between 30±5 and 90±5 days post-stroke
Time frame · At 90±5 days compared to first 30±5 days
Systemic inflammatory markers will be measured using a high-performance biomarker panel for the following 92 proteins (all of which will be informed in pg/mL): ADA; ARTN; AXIN1; NGF; CCL13; CCL19; CCL2; CCL20; CCL23; CCL25; CCL28; CCL3; CCL4; CCL7; CCL8; CXCL10; CXCL11; CXCL5; CXCL6; CXCL9; CDCP1; CASP8; CST5; DNER; CCL11; EIF4EBP1; FGF19; FGF21; FGF23; FGF5; FLT3LG; CX3CL1; GDNF; CXCL1; HGF; IFNG; IL1A; IL10; IL10RA; IL10RB; IL12B; IL13; IL15RA; IL17A; IL17C; IL18; IL18R1; IL2; IL2RB; IL20; IL20RA; IL22RA1; IL24; IL33; IL4; IL5; IL6; IL7; CXCL8; MMP1; KITLG; LIF; LIFR; LTA; CSF1; SIRT2; CD244;NTF3;NRTN;OSM;CD274;S100A12;TGFA;STAMBP;SLAMF1;MMP10;SULT1A1;CD6;CD5;CD8A;TSLP;TGFB1;TNF;TNFSF10;TNFSF11;TNFSF12;TNFSF14;TNFRSF11B;CD40;TNFRSF9;PLAU;VEGFA
Eligibility
Inclusion Criteria: * Age ≥18 years willing to cons Age ≥18 years willing to consent * Patients with acute ischemic stroke in the right or left MCA territory, admitted to University Hospital, London Health Sciences Centre (LHSC) or evaluated at LHSC's Urgent TIA and Stroke Prevention Clinic. Acute ischemic stroke is defined as acute onset focal symptoms matching an acute brain infarct documented on a Head CT or on diffusion weighted imaging (DWI) MRI of the brain showing restricted diffusion. * Willing to consent. Exclusion Criteria: * History of known heart disease defined as known atrial fibrillation, prior myocardial infarction, coronary artery disease, heart failure, prior cardiovascular surgery or percutaneous intervention * Stroke in the previous 3 months before the qualifying stroke. * High-sensitivity Troponin-T (HS-TnT) \>100 ng/L on routine standard of care acute stroke bloodwork. * Clinically or neurologically unstable patients as per the treating physician. * Ongoing infection or recent infection within the previous 3 months. * Surgery within 3 months before the stroke. * Concurrent inflammatory conditions (connective tissue diseases, rheumatological disease, etc.) or use of anti-inflammatory medications. * Contraindications to the use of gadolinium (e.g., pregnancy, stage IV renal insufficiency) * Subjects will be excluded if they fail the St. Joseph's Health Care standard MRI screening questionnaire. Briefly, this questionnaire screens for: Heart Pacemakers / Wires, Aneurysm Clips, Shunt / Surgical Clips, Shrapnel / Bullets, Dentures or Metal braces, Intra-Uterine Device, Heart Valves, Ear Implants, Prostheses, Medication Patches (Nicoderm, Habitrol, Transderm-Nitro, etc.), Claustrophobia, History of a head or eye injury involving metal fragments. Patients with an eGFR \< 40 will be excluded, as impaired renal function places the patient at a higher risk for a rare reaction to Gd-DTPA, the MRI contrast agent.
Study locations
Canada. Showing up to 24 locations stored in the fast local snapshot.
Heart & Brain Lab, Western University
London, Ontario, Canada
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Universidade do Porto · Heart Failure
Not applicable
Recruiting
160
2026-07
Boston Medical Center · Congestive Heart Failure · Volume Overload
Not applicable
Not yet recruiting
200
2026-06
Norfolk and Norwich University Hospitals NHS Foundation Trust · Vascular Surgical Procedure
Not applicable
Recruiting
200
2026-06
China National Center for Cardiovascular Diseases · AKI - Acute Kidney Injury · Cardiac Surgical Procedures
Phase 4
Not yet recruiting
694
2026-06
Cambridge University Hospitals NHS Foundation Trust · Heart Failure
Not applicable
Recruiting
250
2026-05
Chulalongkorn University · Acute Kidney Failure Stage 3
Not applicable
Completed
100
2026-05
Ottawa Heart Institute Research Corporation · Chronic Right-Sided Heart Failure · Pulmonary Arterial Hypertension
Phase 4
Completed
15
2026-05
Novartis · Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Not applicable
Completed
236
2026-04
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.